Results 31 to 40 of about 21,799 (237)

Biosimilar infliximab introduction into the gastro-enterology care pathway in a large acute Irish teaching hospital: a story behind the evidence [PDF]

, 2018
Background and aim: Biosimilar medicines are not considered exact replicas of originator biological medicines. As a result, prescribers can be hesitant to introduce such medicines into the clinical setting until evidence surfaces confirming their safety ...
Byrne, Stephen, Carrol, Donal, Courtney, Garry, Mulcahy, Mark, O'Brien, Gary L., Walshe, Valerie   +5 more
core   +1 more source

Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice

Pharmacology Research & Perspectives, 2020
Recently, biosimilar erythropoietin stimulating agents become available in Kazakhstan. Important properties of the biosimilar such as dose equivalency to the original medicine (originator) and the ability to maintain hemoglobin target levels remain ...
Abduzhappar Gaipov, Alpamys Issanov, Zhanar Mursalova, Nazia Tulegenova, Zoya Kakim, Mukhit Baizakov, Saltanat Tuganbekova, Mohamad Aljofan   +7 more
doaj   +1 more source

Rheumatoid arthritis [PDF]

, 2016
Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor ...
Aletaha, Daniel, McInnes, Iain B., Smolen, Josef S.   +2 more
core   +1 more source

Regulatory Science Ireland: bridging the information gap on biosimilar medicines [PDF]

, 2016
Regulatory Science Ireland (RSI) is a voluntary network of interested parties from academia, the Health Products Regulatory Authority (HPRA), pharmaceutical and medical device industries and government agencies.
Barry, Sean P., Bermingham, Margaret, Griffin, Brendan T., Hallinan, Frank, Moore, Una, Morris, J. Michael, O'Callaghan, Joan   +6 more
core   +1 more source

Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey

Indian Journal of Ophthalmology, 2021
Purpose: The aim of this study was to present the outcomes of the 2018 and 2020 Vitreo-retinal Society of India (VRSI) biosimilars of anti-vascular endothelial growth factor (VEGF) (VIBE) surveys.
Jay U Sheth, Michael W Stewart, Manoj Khatri, Shashank R Gupta, Shobhit Chawla, Anand Rajendran, Raja Narayanan   +6 more
doaj   +1 more source

Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study [PDF]

, 2016
Background Since 2007 biosimilars of erythropoiesis-stimulating agents (ESAs) are available on the Italian market. Very limited post-marketing data exist on the comparative effectiveness of biosimilar and originator ESAs.
Alibrandi, A. (Angela), Bolcato, J. (Jenny), Caputi, A.P. (Achille), Chinellato, A. (Alessandro), Fontana, A. (Andrea), Genazzani, A.A. (Armando A.), Giorgianni, F. (Francesco), Ientile, V. (Valentina), Ingrasciotta, Y. (Ylenia), Marcianò, I. (Ilaria), Pirolo, R. (Roberta), Santoro, D. (Domenico), Trifirò, G. (Gianluca)   +12 more
core   +6 more sources

AI‐Enhanced Vibrational Capsule for Minimally Invasive Detection of Abnormal Bowel Tissue

Advanced Science, EarlyView.
A fully integrated vibration‐assisted capsule is presented for the minimally invasive detection of bowel lesions. The capsule incorporates a wireless sensor and an eccentric motor to probe tissue mechanics in situ. By coupling triaxial vibration signals with AI‐based classification and analytical modeling, the system enables early, non‐visual ...
Xizheng Fang, Yao Yan, Kenneth Omokhagbo Afebu, Andrew Bickerdike, Bo Tian, Yang Liu, Shyam Prasad   +6 more
wiley   +1 more source

Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia

Neurology and Therapy
Introduction TV-46000 is a long-acting subcutaneous antipsychotic (LASCA) agent that combines risperidone and an innovative, copolymer-based drug delivery technology in a suspension suitable for subcutaneous administration from a prefilled syringe.
Itay Perlstein, Avia Merenlender Wagner, Anna Elgart, Anthe S. Zandvliet, Farina Hellmann, YuWei Lin, Eline van Maanen, Nele Plock, Floris Fauchet, Rajendra Singh   +9 more
doaj   +1 more source

Economic aspects of biosimilar competition in Hungary — The treatment of rheumatic disorders [PDF]

, 2017
Biologicals are the fastest growing segment of the global pharmaceutical market, reaching 199 billion USD sales per year with 9.8% 10-year compound annual growth rate (CAGR).
Zrubka, Zsombor
core   +1 more source

Impact of evolving treatment patterns on interstitial lung disease progression in systemic sclerosis using the EUSTAR database

Arthritis &Rheumatology, Accepted Article.
Background The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasing immunosuppressive (IST) and anti‐fibrotic therapies available. However, their real‐world use remains unclear. Objectives To analyze treatment trends and the effect of IST and anti‐fibrotic therapies on ILD progression ...
Corrado Campochiaro, Marie‐Elise Truchetet, Madelon Vonk, Giacomo De Luca, Giovanna Cuomo, Lidia P. Ananieva, Eric Hachulla, Vanessa Smith, Ana Maria Gheorghiu, Radim Becvar, Patricia Carreira, Nicolas Hunzelmann, Daniel E. Furst, Vera Ortiz‐Santamaria, Francesco Del Galdo, Marco Matucci‐Cerinic, Anna‐Maria Hoffmann‐Vold, EUSTAR collaborators   +17 more
wiley   +1 more source